LENZ logo

LENZLENZ Therapeutics Inc.

$7.46
$0.34
(4.37%)
Today
Closed $7.44
$0.02
(0.27%)
After Hours
Updated: 05:39 PM EDT
Reported EarningsMay 11
Mkt Cap$243.94M
Vol975,404.00
News
all
press releases
LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of -20.00% and +15.21%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
More News
News Placeholder
HC Wainwright Expects Weaker Earnings for LENZ Therapeutics
LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Analysts at HC Wainwright reduced their Q1 2026 earnings estimates for LENZ Therapeutics in a research note issued to investors on Tuesday, April...
MarketBeat
News Placeholder
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the firm...
MarketBeat
News Placeholder
LENZ Therapeutics (NASDAQ:LENZ) Price Target Cut to $48.00 by Analysts at HC Wainwright
HC Wainwright reduced their target price on LENZ Therapeutics from $56.00 to $48.00 and set a "buy" rating on the stock in a report on Tuesday...
MarketBeat
News Placeholder
Aberdeen Group plc Increases Holdings in LENZ Therapeutics, Inc. $LENZ
Aberdeen Group plc lifted its position in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 274.4% during the fourth quarter, according to the company in its most recent filing with...
MarketBeat
News Placeholder
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have earned an average rating of "Moderate Buy" from the eight brokerages that are covering the stock, MarketBeat.com reports. One...
MarketBeat
News Placeholder
HC Wainwright Issues Positive Forecast for LENZ Earnings
LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Investment analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for LENZ Therapeutics in a report issued on...
MarketBeat
News Placeholder
Citigroup Has Lowered Expectations for LENZ Therapeutics (NASDAQ:LENZ) Stock Price
Citigroup decreased their price objective on shares of LENZ Therapeutics from $52.00 to $26.00 and set a "buy" rating for the company in a report on Thursday...
MarketBeat
News Placeholder
FY2028 EPS Forecast for LENZ Therapeutics Lowered by Analyst
LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - HC Wainwright lowered their FY2028 earnings per share (EPS) estimates for LENZ Therapeutics in a research note issued on Wednesday, March 25th. HC Wainwright analyst M. Caufield now anticipates that the company will earn $0.62 per share for the y...
MarketBeat
News Placeholder
Bank of America Has Lowered Expectations for LENZ Therapeutics (NASDAQ:LENZ) Stock Price
Bank of America decreased their target price on shares of LENZ Therapeutics from $35.00 to $29.00 and set a "buy" rating on the stock in a research report on Wednesday...
MarketBeat
<
1
2
...
>